Overview

• US gene therapy developer's Q1 net loss narrowed yr/yr, reflecting lower R&D and G&A expenses

• Company monetized Rare Pediatric Disease Priority Review Voucher for $180 mln, extending cash runway

Outlook

• Company expects cash resources to fund operations into Q2 2028

• Rocket anticipates providing a Danon disease program update in H2 2026

Result Drivers

• LOWER OPERATING EXPENSES - Co said net loss narrowed mainly due to reduced R&D and G&A expenses, driven by lower manufacturing, development, and headcount costs, and absence of prior-year legal settlement

• PRV MONETIZATION - Co sold Rare Pediatric Disease Priority Review Voucher for $180 mln, extending operational cash runway

Company press release: ID:nBw2kzm3Ca

Key Details

Metric	Beat/Miss	Actual	Consensus Estimate
Q1 Net Income		-$47.6 mln

Analyst Coverage

• The current average analyst rating on the shares is "hold" and the breakdown of recommendations is 6 "strong buy" or "buy", 6 "hold" and 2 "sell" or "strong sell"

• The average consensus recommendation for the biotechnology & medical research peer group is "buy."

• Wall Street's median 12-month price target for Rocket Pharmaceuticals Inc is $10.00, about 159.1% above its May 6 closing price of $3.86

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.